Evidence map›Paper›PMID 34021798›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2021

Pharmacogenetic association of diabetes-associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors -results of the Heinz Nixdorf Recall Study.

Sonali Pechlivanis, Dominik Jung, Susanne Moebus, Nils Lehmann, Amir A Mahabadi, Per Hoffmann, Raimund Erbel, Markus M Nöthen, Hagen S Bachmann

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Sonali Pechlivanis *Institute of Pharmacology and Toxicology, Centre for Biomedical Education and Research, Witten/Herdecke University, Witten, Germany.
Dominik Jung *Institute of Pharmacology and Toxicology, Centre for Biomedical Education and Research, Witten/Herdecke University, Witten, Germany.ORCID http://orcid.org/0000-0003-4288-6455
Susanne MoebusCentre for Urbane Epidemiology, University Hospital Essen, Essen, Germany.
Nils LehmannInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany.
Amir A MahabadiDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.
Per HoffmannDivision of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland.
Raimund ErbelInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany.
Markus M NöthenInstitute of Human Genetics, School of Medicine & University Hospital Bonn, University of Bonn, Bonn, Germany.
Hagen S BachmannInstitute of Pharmacology and Toxicology, Centre for Biomedical Education and Research, Witten/Herdecke University, Witten, Germany. hagen.bachmann@uni-wh.de.ORCID http://orcid.org/0000-0002-8642-540X
Witten/Herdecke University · DEInstitut für Medizinische Informatik, Biometrie und Epidemiologie · DEUniversity of Bonn · DEEssen University Hospital · DEWest German Heart and Vascular Center Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HMG-CoA-Reductase inhibitors (HMGRIs) are currently the most widely used group of drugs in patients with coronary artery disease (CAD) and are given preemptively to patients with high levels of cholesterol, including those with diabetes mellitus (DM). However, intake of HMGRIs also increases the progression of coronary artery calcification (CAC) and the risk of developing DM. This study aimed to investigate whether HMGRI intake interacts with the diabetes-associated genetic risk score (GRS) to affect CAC progression using data from the population-based Heinz Nixdorf Recall (HNR) study. CAC was measured in 3157 participants using electron-beam computed tomography twice, at baseline (CAC

Indexed as

AgedCoronary Artery DiseaseDiabetes Mellitus, Type 2Disease ProgressionFemaleGenetic Predisposition to DiseaseHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideRisk FactorsTomography, X-Ray ComputedVascular CalcificationHydroxymethylglutaryl-CoA Reductase InhibitorsCohort studyDiabetes mellitusGenetic risk scoreHMG-CoA-reductase inhibitorsPleiotropic effectsProgression of coronary artery calcification

Identifiers

PMID34021798
PMCPMC8298241
OpenAlexW3162994259

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.